Publications

Clinical studies

1. Machiels M. et al. A novel liquid fiducial marker in esophageal cancer image-guided radiotherapy: technical feasibility and visibility on imaging. Pract Radiat Oncol. 2019 Jul 4. [Epub ahead of print]
Link →

2. Ciernik FI. et al. Visualization of the tumor cavity after lumpectomy of breast cancer for postoperative radiotherapy. Clinical and Translational Radiation Oncology 14 (2019) 47–50
Link ->

3. Riisgaard de Blanck S. et al. Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer. Clinical and Translational Radiation Oncology 13 (2018) 24–28
Link →

4. Riisgaard de Blanck S. et al. Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancer. Br J Radiol 2018; 91: 20180236
Link →

5. Scherman Rydhög J. et al. Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer. Radiotherapy and Oncology 123 (2017) 78–84
Link ->

6. Scherman Rydhög J. et al. Liquid fiducial marker applicability in proton therapy of locally advanced lung cancer. Radiotherapy and Oncology 122 (2017) 393–399
Link →

7. Scherman Rydhög J. et al. Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancer. Radiotherapy and Oncology 121 (2016) 64–69
Link →

Non clinical studies

8. Jenny Bertholet et al Real-time intrafraction motion monitoring in external beam radiotherapy. Phys. Med. Biol. 2019; 64 15TR01
Link ->

9. Schneider S. et al. Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3TMRI. Strahlenther Onkol. Published on line 29 May 2019.
Link ->

10. De Roover R. et al. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer. Med. Phys. 45 (5), May 2018
Link ->

11. Schneider S.et al. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom. Med. Phys. 45 (1), January 2018
Link →

12. Dobiasch S. et al. BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model. Experiences with a liquid fiducial marker. Strahlenther Onkol (2017) 193:1039–1047
Link →

13. Jelvehgaran P. et al. Visibility of fiducial markers used for image-guided radiation therapy on optical coherence tomography for registration with CT: An esophageal phantom study. Med. Phys. 44 (12), December 2017.
Link →

14. E. Troost et al. Chemical stability of BioXmark® following normofractionated and single‐fraction proton beam therapy. Radiotherapy and Oncology,2017 Vol. 123, S937–S938.
Link ->

15. V.C. Hamming et al. Visibility, Image Artefacts and Proton Dose Perturbation of Fiducial Markers. Presented at: European Society for Radiotherapy and Oncology (ESTRO) 36, May 5‐9 May 2017, Vienna, Austria.
Link ->

16. Scherman Rydhög J. et al Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. Med. Phys. 42 (6), June 2015.
Link ->

17. Hafeez S et al. Assessing feasibility of a new fudicial marker (BioXmark) for bladder tumor localization and position verification during radical radiotherapy in a porcine phantom. Abstract 30th EUS Annual Meeting, May 16, 2015, New Orleans, LA
Link →

18. Rydhög JS . Artefact quantification of liquid and solid fiducial marker in single and dual energy CT with MAR. Poster. ESTRO 3 FORUM, April 24-28, 2015, Barcelona, Spain
Link →

19. Mortensen SR. et al. Use of Novel Liquid Fiducial Marker Injected With Endoscopic Ultrasound Equipment for Use in Image Guided Radiation Therapy of Thoracic Tumors (Porcine Model). International Journal of Radiation Oncology, Biolgy, Physics. Volume 90, Issue 1, Supplement, page S651, September 1, 2014.
Link ->